Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Immune activation and HIV persistence: considerations for novel therapeutic interventions.

Hatano H.

Curr Opin HIV AIDS. 2013 May;8(3):211-6. doi: 10.1097/COH.0b013e32835f9788. Review.

PMID:
23454864
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Immune activation, HIV persistence, and the cure.

Douek DC.

Top Antivir Med. 2013 Sep-Oct;21(4):128-32.

PMID:
24225078
[PubMed - indexed for MEDLINE]
Free Article
3.

Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.

Pierson T, McArthur J, Siliciano RF.

Annu Rev Immunol. 2000;18:665-708. Review.

PMID:
10837072
[PubMed - indexed for MEDLINE]
4.

Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia.

Karlsson AC, Younger SR, Martin JN, Grossman Z, Sinclair E, Hunt PW, Hagos E, Nixon DF, Deeks SG.

AIDS. 2004 Apr 30;18(7):981-9.

PMID:
15096800
[PubMed - indexed for MEDLINE]
5.

HIV and inflammation: mechanisms and consequences.

Hunt PW.

Curr HIV/AIDS Rep. 2012 Jun;9(2):139-47. doi: 10.1007/s11904-012-0118-8. Review.

PMID:
22528766
[PubMed - indexed for MEDLINE]
6.

Th17, gut, and HIV: therapeutic implications.

Hunt PW.

Curr Opin HIV AIDS. 2010 Mar;5(2):189-93. doi: 10.1097/COH.0b013e32833647d9. Review.

PMID:
20543599
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.

Chun TW, Justement JS, Murray D, Hallahan CW, Maenza J, Collier AC, Sheth PM, Kaul R, Ostrowski M, Moir S, Kovacs C, Fauci AS.

AIDS. 2010 Nov 27;24(18):2803-8. doi: 10.1097/QAD.0b013e328340a239.

PMID:
20962613
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

The role of cytokines in the establishment, persistence and eradication of the HIV reservoir.

Vandergeeten C, Fromentin R, Chomont N.

Cytokine Growth Factor Rev. 2012 Aug-Oct;23(4-5):143-9. doi: 10.1016/j.cytogfr.2012.05.001. Epub 2012 Jun 27. Review.

PMID:
22743037
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

The development of immune-modulating compounds to disrupt HIV latency.

Remoli AL, Marsili G, Battistini A, Sgarbanti M.

Cytokine Growth Factor Rev. 2012 Aug-Oct;23(4-5):159-72. doi: 10.1016/j.cytogfr.2012.05.003. Epub 2012 Jul 4. Review.

PMID:
22766356
[PubMed - indexed for MEDLINE]
10.

Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses.

Luzuriaga K, McManus M, Catalina M, Mayack S, Sharkey M, Stevenson M, Sullivan JL.

J Virol. 2000 Aug;74(15):6984-91.

PMID:
10888637
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Immune activation and HIV persistence: implications for curative approaches to HIV infection.

Klatt NR, Chomont N, Douek DC, Deeks SG.

Immunol Rev. 2013 Jul;254(1):326-42. doi: 10.1111/imr.12065. Review.

PMID:
23772629
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.

Steel A, Cox AE, Shamji MH, John L, Nelson M, Henderson DC, Gotch FM, Gazzard BG, Kelleher P.

Antivir Ther. 2007;12(6):971-5.

PMID:
17926652
[PubMed - indexed for MEDLINE]
13.

Vaccine and immunotherapeutic interventions.

Pantaleo G, Lévy Y.

Curr Opin HIV AIDS. 2013 May;8(3):236-42. doi: 10.1097/COH.0b013e32835fd5cd. Review.

PMID:
23478912
[PubMed - indexed for MEDLINE]
14.

Will it be possible to live without antiretroviral therapy?

Hamimi C, Pancino G, Barré-Sinoussi F, Sáez-Cirión A.

Curr Opin HIV AIDS. 2013 May;8(3):196-203. doi: 10.1097/COH.0b013e32835f94d5. Review.

PMID:
23422261
[PubMed - indexed for MEDLINE]
15.

Can HIV be Cured? Mechanisms of HIV persistence and strategies to combat it.

Hamer DH.

Curr HIV Res. 2004 Apr;2(2):99-111. Review.

PMID:
15078175
[PubMed - indexed for MEDLINE]
16.

Altering cell death pathways as an approach to cure HIV infection.

Badley AD, Sainski A, Wightman F, Lewin SR.

Cell Death Dis. 2013 Jul 11;4:e718. doi: 10.1038/cddis.2013.248. Review.

PMID:
23846220
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Immune control of HIV-1 reservoirs.

Autran B, Descours B, Bacchus C.

Curr Opin HIV AIDS. 2013 May;8(3):204-10. doi: 10.1097/COH.0b013e32835fe6d2. Review.

PMID:
23493099
[PubMed - indexed for MEDLINE]
18.

Tracking replication-competent HIV reservoirs in infected individuals.

Chun TW.

Curr Opin HIV AIDS. 2013 Mar;8(2):111-6. doi: 10.1097/COH.0b013e32835d6e1c. Review.

PMID:
23380652
[PubMed - indexed for MEDLINE]
19.

Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.

Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslén M.

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):168-73.

PMID:
17971711
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

HIV reservoirs: pathogenesis and obstacles to viral eradication and cure.

Chun TW, Fauci AS.

AIDS. 2012 Jun 19;26(10):1261-8. doi: 10.1097/QAD.0b013e328353f3f1. Review.

PMID:
22472858
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk